Collagen Type XVI Assay for Early Colorectal Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively detect and diagnose colorectal cancer, ulcerative colitis, and fibrostenotic strictures in Crohn’s disease, as they lack reliable biomarkers for early detection and monitoring, leading to delayed diagnosis and treatment.
Innovation Solution
A method involving the use of a monoclonal antibody specifically reactive with the C-terminus biomarker sequence PMKTMKGPFG, which is used to detect collagen type XVI or its fragments in biofluid samples, allowing for quantitative assessment and prediction of these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for colorectal cancer, ulcerative colitis, and Crohn's disease, then diagnosis can be performed, but early detection and monitoring are delayed due to lack of reliable biomarkers
Solution Approach 1:
The patent applies preliminary action by developing and validating a biomarker assay (collagen type XVI) that can detect disease presence and progression before clinical symptoms manifest. The assay enables early detection of colorectal cancer, ulcerative colitis, and fibrostenotic strictures by measuring collagen type XVI levels in biofluids, allowing intervention before disease progression to later stages.
2Measurement precision
If invasive procedures are used for diagnosis, then accurate detection can be achieved, but patient comfort decreases and treatment costs increase
Solution Approach 1:
The patent replaces mechanical/invasive diagnostic procedures with a biochemical assay system. Instead of using endoscopy, biopsy, or other invasive mechanical methods to detect disease, the invention uses a serum or plasma-based collagen type XVI assay that can be performed on simple blood draws, thereby maintaining diagnostic accuracy while eliminating patient discomfort associated with invasive procedures.
3Measurement precision
If invasive procedures are used for diagnosis, then accurate detection can be achieved, but procedural complexity and cost increase
Solution Approach 1:
The patent extracts the diagnostic function from complex invasive procedures and concentrates it into a single biomarker measurement. By identifying collagen type XVI as a specific diagnostic marker, the invention extracts the essential diagnostic information that would otherwise require complex endoscopic or surgical procedures, thereby simplifying the diagnostic workflow while maintaining accuracy.
4Reliability
If current diagnostic approaches are used, then disease can be detected, but monitoring of disease progression and treatment response is insufficient
Solution Approach 1:
The patent implements feedback by enabling repeated measurement of collagen type XVI levels over time to monitor disease progression and treatment response. The assay provides quantitative data that feeds back into clinical decision-making, allowing physicians to adjust treatment based on objective biomarker changes rather than waiting for clinical symptom changes, thereby improving diagnostic reliability and providing continuous disease status information.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables early and accurate detection of colorectal cancer, ulcerative colitis, and identification of patients likely to develop fibrostenotic strictures, potentially reducing the need for invasive procedures and improving treatment outcomes by providing a non-invasive, predictive diagnostic tool.
Implementation Method 1
contacting the biofluid sample with a monoclonal antibody specifically reactive with a C-terminus biomarker having the C-terminus amino acid sequence PMKTMKGPFG (SEQ ID NO: 1) and detecting binding between the biomarker and the antibody
Data Source
AI summary
The present invention relates to a type XVI collagen assay and its use in evaluating diseases associated with type XVI collagen, in particular colorectal cancer and ulcerative colitis, and for identifying a subgroup of patients with Crohn’s disease that have (or are likely to develop) fibrostenotic strictures.